How to train your biomarker

Clinical Cancer Research

Volumn 16, Issue 12, 2010, Pages 3091-3093

  Yee, Douglas ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; FIGITUMUMAB; INSULIN; INSULIN RECEPTOR; OSI 906; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; IN VITRO STUDY; LIGAND BINDING; PREDICTION; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; GENE EXPRESSION PROFILING; HUMANS; LIGANDS; PROTEIN KINASE INHIBITORS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77953696423     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0873     Document Type: Short Survey

References (13)

1. Pitts TM, Tan AK, Kulikowski GN, et al. Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res 2010;16:3193-204.
2. Kaleko M, Rutter WJ, Miller AD. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 1990;10:464-73. (Pubitemid 20034451)
3. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
4. Gualberto A. Figitumumab (CP-751,871) for cancer therapy. Expert Opin Biol Ther 2010;10:575-85.
5. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-40.
6. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-13.
7. Mardilovich K, Pankratz SL, Shaw LM. Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal 2009;7:14.
8. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.
9. Creighton CJ, Casa A, Lazard Z, et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008;26:4078-85.
10. Litzenburger BC, Tsimelzon A, Hilsenbeck SG, et al. High IGF-IR activity in triple-negative breast cancer cell lines correlates with sensitivity to IGF-IR inhibitor BMS-754807 in this subtype of human breast cancer. Cancer Res 2009;69:1132.
11. Rajski M, Zanetti-Dallenbach R, Vogel B, Herrmann R, Rochlitz C, Buess M. IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. BMC Med 2010;8:1.
12. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2009;11:129-35.
13. Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the antiinsulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27:2516-22.